Abstract
To ensure the safe administration of vaccines to humans, vaccines (just like any new chemical entity) are evaluated in a series of nonclinical safety assessment studies that aim at identifying the potential toxicities associated with their administration. The nonclinical safety assessment of vaccines, however, is only part of a testing battery performed prior to human administration, which includes (1) the evaluation of the vaccine in efficacy and immunogenicity studies in animal models, (2) a quality control testing program, and (3) toxicology (nonclinical safety assessment) testing in relevant animal models. Although each of these evaluations plays a critical role in ensuring vaccine safety, the nonclinical safety assessment is the most relevant to the evaluation in human clinical trials, as it allows the identification of potential toxicities to be monitored in human trials, and in some cases, eliminates candidates that have unacceptable risks for human testing. This review summarizes the requirements for the nonclinical testing of vaccines and adjuvants needed in support of all phases of human clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
WHO Guidelines on Nonclinical Evaluation of Vaccines. (2003) WHO/BS/03.1969. WHO, Geneva, Switzerland.
Note for Guidance on Preclinical Pharmacological and Toxicological Testing of Vaccines. (1997) EMEA. CPMP/SWP/465/95.
Guideline on Adjuvants in Vaccines for Human Use. (2005) EMEA. EMEA/CHMP/VEG/134716/2004.
Good Laboratory Practice Regulations. (2009) Code of Federal Regulations, Title 21, Part 58 (21 CFR 58).
Guidelines for Assuring the Quality and Nonclinical Safety Evaluation of DNA Vaccines (2005) WHO, Geneva, Switzerland.
ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. (1997) International Conference on Harmonization.
Note for Guidance on Pharmaceutical and Biological Aspects of Combined Vaccines. (1998) EMEA. CPMP/BWP/477/98.
Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products. (2001) EMEA. CPMP/BWP/3088/99.
Points to Consider on the Manufacture and Quality Control of Human Somatic Cell Therapy Medicinal Products. (2001) EMEA. CPMP/BWP/41450/98.
General Biological Products Standards. (2009) Code of Federal Regulations, Title 21, Part 610 (21 CFR 610).
Guidance for Industry. Considerations for Developmental Toxicity Studies for Preventative and Therapeutic Vaccines for Infectious Disease Indications. (2006) CBER, FDA.
Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications. (2007) CBER, FDA.
Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. (1998) CBER, FDA.
Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology. (1985) CBER, FDA.
Opalka, D., Lachman, C. E., MacMullen, S. A., et al. (2003) Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10, 108–115.
Casimiro, D. R., Tang, A., Perry, H. C., et al. (2002) Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J Virol 76, 185–194.
Gruber, M. F. (2003) Non-clinical safety assessment of vaccines, in CBER Counter Terrorism Workshop, Bethesda, MD.
ICH. (2000) Safety Pharmacology Studies for Human Pharmaceuticals. Topic S7A, Step 5, ICH Harmonized Tripartite Guideline. International Conference on Harmonization, Geneva, Switzerland.
ICH. (1997) S2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals. International Conference on Harmonization, Geneva, Switzerland.
The Organisers, IABs. (2006) IABs scientific workshop on neurovirulence tests for live virus vaccines. Biologicals 34, 233–236.
Acknowledgments
The authors would like to thank Dr. Brian Ledwith and Dr. Tom Monticello for reviewing this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Wolf, J.J., Kaplanski, C.V., Lebron, J.A. (2010). Nonclinical Safety Assessment of Vaccines and Adjuvants. In: Davies, G. (eds) Vaccine Adjuvants. Methods in Molecular Biology, vol 626. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-585-9_3
Download citation
DOI: https://doi.org/10.1007/978-1-60761-585-9_3
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-584-2
Online ISBN: 978-1-60761-585-9
eBook Packages: Springer Protocols